Released Feb 26, 2019, after the close
10-K filed Feb 26, 2019, 57 days after period end · 0001232524-19-000013
Q4 2018 · 10-K
Revenue$476.46M$476.46M +9.2% vs Q4 2017+1.5% vs Q3 2018
Net Income$159.47M$159.47M −31.3% vs Q4 2017+6.8% vs Q3 2018
EPS Diluted$2.64$2.64 −30.3% vs Q4 2017+9.5% vs Q3 2018
Gross Profit$440,997,000+8.9%
Operating Incomederived$185,055,000+31.1%
Operating Cash Flowderived$218,096,000+6.6%
Free Cash Flowderived$212,947,000+8.8%
Margins · derived
Gross margin92.6%−0.2 pt vs Q4 2017
Operating margin38.8%+6.5 pt vs Q4 2017
Net margin33.5%−19.7 pt vs Q4 2017
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $476.46M | $436.40M | $396.62M | $340.88M |
| Net Income | $159.47M | $232.21M | $116.69M | $82.76M |
| EPS Diluted | $2.64 | $3.79 | $1.91 | $1.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR